115
Views
0
CrossRef citations to date
0
Altmetric
Patent Evaluation

Bitopic muscarinic agonists and antagonists and uses thereof: a patent evaluation of US20160136145A1

&
Pages 121-125 | Received 14 Sep 2016, Accepted 07 Dec 2016, Published online: 26 Dec 2016

References

  • Lane JR, Sexton PM, Christopoulos A. Trends bridging the gap: bitopic ligands of G-protein-coupled receptors. Trends Pharmacol Sci. 2013;34:59–66.
  • Schwyzer R. ACTH: a short introductory review. Ann N Y Acad Sci. 1977;297:3–26.
  • Steinfeld T, Mammen M, Smith JA, et al. THR-160209, a novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. Mol Pharmacol. 2007;72:291–302.
  • Disingrini T, Muth M, Dallanoce C, et al. Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors. J Med Chem. 2006;49:366–372.
  • Schrage R, Seemann WK, Klöckner J, et al. Agonists with supraphysiological efficacy at the muscarinic M2 ACh receptor. Br J Pharmacol. 2013;169:357–370.
  • Antony J, Kellershohn K, Mohr-Andrä M, et al. Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB J. 2009;23:442–450.
  • Bock A, Merten N, Schrage R, et al. The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling. Nat Commun. 2012;3:1044.
  • Bock A, Kostenis E, Tränkle C, et al. Pilot the pulse: controlling the multiplicity of receptor dynamics. Trends Pharmacol Sci. 2014;35:630–638.
  • Bock A, Chirinda B, Krebs F, et al. Dynamic ligand binding dictates partial agonism at a G protein-coupled receptor. Nat Chem Biol. 2014;10:18–20.
  • Chen X, Klöckner J, Holze J, et al. Rational design of partial agonists for the muscarinic m1 acetylcholine receptor. J Med Chem. 2015;58:560–576.
  • Bock A, Bermudez M, Krebs F, et al. Ligand binding ensembles determine graded agonist efficacies at a G protein-coupled receptor. J Biol Chem. 2016;291:16375–16389.
  • Decker M, Holzgrabe U. M1 muscarinic acetylcholine receptor allosteric modulators as potential therapeutic opportunities for treating Alzheimer’s disease. MedChemCommun. 2012;3:752–762.
  • Tahtaoui C, Parrot I, Klotz P, et al. Fluorescent pirenzepine derivatives as potential bitopic ligands of the human M1 muscarinic receptor. J Med Chem. 2004;47:4300–4315.
  • Mohr K, Schmitz J, Schrage R, et al. Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors. Angew Chem Int Ed Engl. 2013;52:508–516.
  • Schmitz J, van der Mey D, Bermudez M, et al. Dualsteric muscarinic antagonists–orthosteric binding pose controls allosteric subtype selectivity. J Med Chem. 2014;57:6739–6750.
  • Valant C, Gregory KJ, Hall NE, et al. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J Biol Chem. 2008;283:29312–29321.
  • Boulos J, Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof. US2016/0136145 A1. 2016.
  • Schulman JM, Sabio ML, Disch RL. Recognition of cholinergic agonists by the muscarinic receptor. 1. Acetylcholine and other agonists with the NCCOCC backbone. J Med Chem. 1983;26:817–823.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.